Text Size

Study Evaluating Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00227240
First received: September 13, 2005
Last updated: March 20, 2012
Last verified: March 2012
History of Changes
  Purpose

The purpose of this study is to investigate the incidences of adverse events for patients with plaque psoriasis treated with Enbrel under usual care settings.


Condition
Plaque Psoriasis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Study With Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis

Resource links provided by NLM:

MedlinePlus related topics: Psoriasis
Drug Information available for: Etanercept
U.S. FDA Resources

Further study details as provided by Pfizer:

Enrollment: 753
Study Start Date: April 2005
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

primary care clinical and community sample

Criteria

Inclusion Criteria:

  • Proven diagnosis of Plaque Psoriasis

Exclusion Criteria:

  • Contraindications according to SmPC of Enbrel
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00227240

Locations
Germany
Pfizer Investigational Site
Muenchen, Germany, 80337
Pfizer Investigational Site
Munich, Germany, 81366
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00227240     History of Changes
Other Study ID Numbers: 0881A-101789
Study First Received: September 13, 2005
Last Updated: March 20, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
TNFR-Fc fusion protein
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
 Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Gastrointestinal Agents
Immunologic Factors
Immunosuppressive Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 23, 2013